Apogee Therapeutics, Inc. Common Stock (APGE) — the earnings record
Computed on 2026-09-18 from the vendor's per-print history with the Print Record's method — no desk-written read yet. An investment research diary, not advice.
The record at a glance
Reactions across the covered prints span -17.6% to +12.9% — the beat column and the reaction column frequently disagree, which is the whole reason the record scores them separately. The street carries est EPS $-1.14 · est revenue ~$0.00B into the next print.
Print by print
| Date | EPS | Revenue | |
|---|---|---|---|
| Aug 26 | 2026-08-10 | ✗ miss | ✗ miss |
| May 26 | 2026-05-11 | ✓ beat | ✗ miss |
| Mar 26 | 2026-03-02 | ✓ beat | ✗ miss |
| Nov 25 | 2025-11-10 | ✓ beat | ✗ miss |
| Aug 25 | 2025-08-11 | ✗ miss | ✗ miss |
| May 25 | 2025-05-12 | ✓ beat | ✗ miss |
| Mar 25 | 2025-03-03 | ✗ miss | ✗ miss |
| Nov 24 | 2024-11-12 | ✓ beat | ✗ miss |
| Aug 24 | 2024-08-12 | ✓ beat | ✗ miss |
| May 24 | 2024-05-13 | ✗ miss | ✗ miss |
Report-day close to the close three sessions later on adjusted closes, ±3% bands — the same method as every hand-written card; the Print Record method explains the bands. No reaction chart, metric line or behavior read exists for APGE yet.
FAQ · from the current data · as of 2026-09-18
Quick answers
How often does Apogee Therapeutics, Inc. Common Stock beat earnings estimates?
Across the last 10 covered prints (as of the 2026-09-18 card), Apogee Therapeutics, Inc. Common Stock beat EPS estimates 6 of 10 times and revenue estimates 0 of 10 times, with 0 double beats.
How does APGE stock react to earnings?
Measured close-of-print-day to the close three sessions later: 3 of the last 10 prints resolved up (beyond +3%), 6 flat, 1 down — reactions spanning -17.6% to +12.9%. Beat-or-miss and reaction are scored separately because they frequently disagree.
What was APGE's biggest earnings reaction?
-17.6% over the three sessions after the Nov 24 print (2024-11-12).
When does Apogee Therapeutics, Inc. Common Stock report earnings next?
2026-11-09 (2026-11-09 · est EPS $-1.14 · est revenue ~$0.00B). This record is computed from the vendor's per-print history with the Print Record's method; a desk-written card for APGE does not exist yet. An investment research diary, not advice.
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- ONC BeiGene, Ltd.industry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- SMMT Summit Therapeutics PLCindustry
- HALO Halozyme Therapeutics Incindustry
- TLX.AU TELIX Pharmaceuticals Ltdindustry
- SRPT Sarepta Therapeutics Incindustry
- GMAB Genmab ASindustry
- IBRX Immunitybio Incindustry
- CRSP Crispr Therapeutics AGindustry
- EXEL Exelixis Incindustry
- TGTX TG Therapeutics Incindustry
- MRVI Maravai Lifesciences Holdings Incindustry
- INCY Incyte Corporationindustry